Olabir 150 mg contains Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor designed to target cancer cells with defective DNA repair mechanisms, particularly those with BRCA1 or BRCA2 mutations.

🔬 Mechanism of Action

Olaparib blocks the PARP enzyme, which plays a crucial role in repairing single-strand DNA breaks. In cancer cells with BRCA mutations, DNA repair is already compromised. By inhibiting PARP, Olaparib causes accumulation of DNA damage, leading to cancer cell death while minimizing effects on normal cells.

💊 Indications

Olabir 150 mg is indicated for:

• BRCA-mutated advanced ovarian cancer (maintenance therapy or recurrent disease)
• HER2-negative, BRCA-mutated metastatic breast cancer
• Metastatic pancreatic cancer with germline BRCA mutation
• Metastatic castration-resistant prostate cancer (mCRPC) with HRR gene mutations

It is typically prescribed after specific prior treatments, depending on the cancer type and clinical guidelines.

📌 Key Features of Olabir 150 mg

• Strength: 150 mg
• Dosage Form: Oral tablet
• Therapeutic Class: PARP Inhibitor
• Administration: Taken orally, usually twice daily as prescribed
• Monitoring: Regular complete blood count (CBC) and clinical evaluation required

⚕️ Benefits of Olaparib

• Targeted therapy for BRCA and HRR-mutated cancers
• Helps prolong progression-free survival
• Oral administration for patient convenience
• Precision oncology approach

⚠️ Precautions

• May cause anemia, nausea, fatigue, and decreased appetite
• Risk of myelodysplastic syndrome (MDS) or acute myeloid leukemia (rare)
• Regular blood monitoring required
• Avoid during pregnancy and breastfeeding
• Use strictly under oncologist supervision

Olabir 150 mg (Olaparib Tablets) provides a precision-targeted treatment option for BRCA and HRR-mutated cancers, helping improve clinical outcomes and offering an effective maintenance therapy approach in modern oncology care.